The global cancer immunotherapy market is expected to reach USD 231,338.41 million by 2031 from USD 83,575.21 million in 2023, growing at a CAGR of 14.5% during the forecast period of 2024 to 2031.
Market Segmentation
Global Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.
Overview of Global Cancer Immunotherapy Market Dynamics
- Driver
- Rising prevalence of cancer incidences
- Restraint
- Increasing occurrence of immune-related adverse events
- Opportunity
- Growing trend towards combination therapies
Market Players
Some of the major market players operating in the global cancer immunotherapy market are:
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Janssen Pharmaceutical
- AstraZeneca
- Gilead Sciences, Inc.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- GSK
- Pfizer Inc.
- Incyte
TABLE OF CONTENTS
1 INTRODUCTION 84
- 1.1 OBJECTIVES OF THE STUDY 84
- 1.2 MARKET DEFINITION 84
- 1.3 OVERVIEW OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET 84
- 1.4 CURRENCY AND PRICING 86
- 1.5 LIMITATIONS 86
- 1.6 MARKETS COVERED 86
2 MARKET SEGMENTATION 90
- 2.1 MARKETS COVERED 90
- 2.2 GEOGRAPHICAL SCOPE 91
- 2.3 YEARS CONSIDERED FOR THE STUDY 92
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 93
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
- 2.6 MULTIVARIATE MODELLING 97
- 2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 97
- 2.8 MARKET END USER COVERAGE GRID 98
- 2.9 DBMR MARKET POSITION GRID 99
- 2.10 VENDOR SHARE ANALYSIS 100
- 2.11 SECONDARY SOURCES 101
- 2.12 ASSUMPTIONS 101
3 EXECUTIVE SUMMARY 102
4 PREMIUM INSIGHTS 104
- 4.1 PESTAL ANALYSIS 107
- 4.2 PORTERS 5 FORCES 108
5 GLOBAL CANCER IMMUNOTHERAPY MARKET: REGULATIONS 109
6 MARKET OVERVIEW 117
- 6.1 DRIVERS 119
- 6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 119
- 6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 119
- 6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 120
- 6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 120
- 6.2 RESTRAINTS 121
- 6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 121
- 6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 121
- 6.3 OPPORTUNITIES 122
- 6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 122
- 6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 122
- 6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 123
- 6.4 CHALLENGES 124
- 6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 124
- 6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 124
7 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE 125
- 7.1 OVERVIEW 126
- 7.2 CHECKPOINT INHIBITORS 129
- 7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 130
- 7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 130
- 7.3 MONOCLONAL ANTIBODIES 131
- 7.3.1 NAKED MONOCLONAL ANTIBODIES 132
- 7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 132
- 7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 132
- 7.4 VACCINES 133
- 7.4.1 PROPHYLACTIC VACCINES 134
- 7.4.2 THERAPEUTIC VACCINES 134
- 7.5 CELL THERAPIES 134
- 7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 135
- 7.5.2 T CELL THERAPY 135
- 7.6 IMMUNOMODULATORS 135
- 7.6.1 INTERFERONS 136
- 7.6.2 INTERLEUKINS 136
- 7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 136
- 7.7 ONCOLYTIC VIRUS 137
8 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER 138
- 8.1 OVERVIEW 139
- 8.2 HOSPITALS 142
- 8.3 ONCOLOGY CLINICS 143
- 8.4 HOMECARE 143
- 8.5 OTHERS 144
9 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 145
- 9.1 OVERVIEW 146
- 9.2 DIRECT TENDERS 149
- 9.3 RETAIL SALES 150
- 9.4 PHARMACIES 150
- 9.4.1 HOSPITAL 151
- 9.4.2 RETAIL 151
- 9.4.3 ONLINE 151
10 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY FORM 152
- 10.1 OVERVIEW 153
- 10.2 INTRAVENOUS (IV) 156
- 10.3 INTRAMUSCULAR 157
- 10.4 ORAL 157
11 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 158
- 11.1 OVERVIEW 159
- 11.2 LUNG CANCER 162
- 11.2.1 CHECKPOINT INHIBITORS 163
- 11.2.2 MONOCLONAL ANTIBODIES 163
- 11.2.3 CELL THERAPIES 163
- 11.2.4 IMMUNOMODULATORS 163
- 11.3 BREAST CANCER 164
- 11.3.1 CHECKPOINT INHIBITORS 164
- 11.3.2 MONOCLONAL ANTIBODIES 164
- 11.3.3 CELL THERAPIES 165
- 11.3.4 IMMUNOMODULATORS 165
- 11.4 MELANOMA 165
- 11.4.1 CHECKPOINT INHIBITORS 166
- 11.4.2 MONOCLONAL ANTIBODIES 166
- 11.4.3 CELL THERAPIES 166
- 11.4.4 IMMUNOMODULATORS 166
- 11.4.5 ONCOLYTIC VIRUS 166
- 11.5 MULTIPLE MYELOMA 167
- 11.5.1 CHECKPOINT INHIBITORS 167
- 11.5.2 MONOCLONAL ANTIBODIES 167
- 11.5.3 CELL THERAPIES 167
- 11.5.4 IMMUNOMODULATORS 168
- 11.6 PROSTATE CANCER 168
- 11.6.1 CHECKPOINT INHIBITORS 168
- 11.6.2 MONOCLONAL ANTIBODIES 169
- 11.6.3 CELL THERAPIES 169
- 11.6.4 IMMUNOMODULATORS 169
- 11.6.5 VACCINES 169
- 11.7 OVARIAN CANCER 169
- 11.7.1 CHECKPOINT INHIBITORS 170
- 11.7.2 MONOCLONAL ANTIBODIES 170
- 11.7.3 CELL THERAPIES 170
- 11.7.4 IMMUNOMODULATORS 170
- 11.8 CERVICAL CANCER 171
- 11.8.1 CHECKPOINT INHIBITORS 171
- 11.8.2 MONOCLONAL ANTIBODIES 171
- 11.8.3 VACCINES 172
- 11.8.4 CELL THERAPIES 172
- 11.8.5 IMMUNOMODULATORS 172
- 11.9 STOMACH CANCER 172
- 11.9.1 CHECKPOINT INHIBITORS 173
- 11.9.2 MONOCLONAL ANTIBODIES 173
- 11.9.3 CELL THERAPIES 173
- 11.9.4 IMMUNOMODULATORS 173
- 11.10 COLORECTAL CANCER 173
- 11.10.1 CHECKPOINT INHIBITORS 174
- 11.10.2 MONOCLONAL ANTIBODIES 174
- 11.10.3 CELL THERAPIES 174
- 11.10.4 IMMUNOMODULATORS 174
- 11.11 HEAD AND NECK CANCER 175
- 11.11.1 CHECKPOINT INHIBITORS 175
- 11.11.2 MONOCLONAL ANTIBODIES 175
- 11.11.3 CELL THERAPIES 175
- 11.11.4 IMMUNOMODULATORS 176
- 11.12 OTHERS 176
- 11.12.1 CHECKPOINT INHIBITORS 176
- 11.12.2 MONOCLONAL ANTIBODIES 176
- 11.12.3 VACCINES 177
- 11.12.4 CELL THERAPIES 177
- 11.12.5 IMMUNOMODULATORS 177
12 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION 178
- 12.1 OVERVIEW 179
- 12.2 NORTH AMERICA 182
- 12.2.1 U.S. 190
- 12.2.2 CANADA 198
- 12.2.3 MEXICO 206
- 12.3 EUROPE 214
- 12.3.1 GERMANY 222
- 12.3.2 FRANCE 230
- 12.3.3 ITALY 238
- 12.3.4 SPAIN 246
- 12.3.5 U.K. 254
- 12.3.6 SWITZERLAND 262
- 12.3.7 NETHERLANDS 270
- 12.3.8 RUSSIA 278
- 12.3.9 TURKEY 286
- 12.3.10 POLAND 294
- 12.3.11 HUNGARY 302
- 12.3.12 LITHUANIA 310
- 12.3.13 AUSTRIA 318
- 12.3.14 IRELAND 326
- 12.3.15 NORWAY 334
- 12.3.16 REST OF EUROPE 342
- 12.4 ASIA-PACIFIC 343
- 12.4.1 CHINA 352
- 12.4.2 JAPAN 360
- 12.4.3 INDIA 368
- 12.4.4 SOUTH KOREA 376
- 12.4.5 AUSTRALIA 384
- 12.4.6 SINGAPORE 393
- 12.4.7 THAILAND 402
- 12.4.8 INDONESIA 410
- 12.4.9 PHILIPPINES 419
- 12.4.10 MALAYSIA 428
- 12.4.11 VIETNAM 436
- 12.4.12 REST OF ASIA-PACIFIC 444
- 12.5 SOUTH AMERICA 445
- 12.5.1 BRAZIL 453
- 12.5.2 ARGENTINA 461
- 12.5.3 PERU 469
- 12.5.4 REST OF SOUTH AMERICA 477
- 12.6 MIDDLE EAST AND AFRICA 478
- 12.6.1 SOUTH AFRICA 486
- 12.6.2 SAUDI ARABIA 494
- 12.6.3 U.A.E. 502
- 12.6.4 EGYPT 510
- 12.6.5 ISRAEL 518
- 12.6.6 OMAN 526
- 12.6.7 QATAR 534
- 12.6.8 BAHRAIN 542
- 12.6.9 REST OF MIDDLE EAST AND AFRICA 550
13 GLOBAL CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 551
- 13.1 COMPANY SHARE ANALYSIS: GLOBAL 551
- 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 552
- 13.3 COMPANY SHARE ANALYSIS: EUROPE 553
- 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 554
14 SWOT ANALYSIS 555
15 COMPANY PROFILES 556
- 15.1 MERCK & CO., INC. 556
- 15.1.1 COMPANY SNAPSHOT 556
- 15.1.2 REVENUE ANALYSIS 556
- 15.1.3 COMPANY SHARE ANALYSIS 557
- 15.1.4 PRODUCT PORTFOLIO 557
- 15.1.5 RECENT DEVELOPMENTS 557
- 15.2 F. HOFFMANN-LA ROCHE LTD 558
- 15.2.1 COMPANY SNAPSHOT 558
- 15.2.2 REVENUE ANALYSIS 558
- 15.2.3 COMPANY SHARE ANALYSIS 559
- 15.2.4 PRODUCT PORTFOLIO 559
- 15.2.5 RECENT DEVELOPMENTS 559
- 15.3 BRISTOL-MYERS SQUIBB COMPANY 561
- 15.3.1 COMPANY SNAPSHOT 561
- 15.3.2 REVENUE ANALYSIS 561
- 15.3.3 COMPANY SHARE ANALYSIS 562
- 15.3.4 PRODUCT PORTFOLIO 562
- 15.3.5 RECENT DEVELOPMENTS 563
- 15.4 JANSSEN GLOBAL SERVICES, LLC 564
- 15.4.1 COMPANY SNAPSHOT 564
- 15.4.2 REVENUE ANALYSIS 564
- 15.4.3 COMPANY SHARE ANALYSIS 565
- 15.4.4 PRODUCT PORTFOLIO 565
- 15.4.5 RECENT DEVELOPMENTS 566
- 15.5 ASTRAZENECA 567
- 15.5.1 COMPANY SNAPSHOT 567
- 15.5.2 REVENUE ANALYSIS 567
- 15.5.3 COMPANY SHARE ANALYSIS 568
- 15.5.4 PRODUCT PORTFOLIO 568
- 15.5.5 RECENT DEVELOPMENTS 569
- 15.6 ABBVIE INC. 570
- 15.6.1 COMPANY SNAPSHOT 570
- 15.6.2 PIPELINE PORTFOLIO 570
- 15.6.3 RECENT DEVELOPMENTS 570
- 15.7 AMGEN INC. 571
- 15.7.1 COMPANY SNAPSHOT 571
- 15.7.2 REVENUE ANALYSIS 572
- 15.7.3 PIPELINE PORTFOLIO 572
- 15.7.4 PRODUCT PORTFOLIO 573
- 15.7.5 RECENT DEVELOPMENTS 573
- 15.8 ATARA BIOTHERAPEUTICS, INC. 574
- 15.8.1 COMPANY SNAPSHOT 574
- 15.8.2 PIPELINE PORTFOLIO 574
- 15.8.3 RECENT DEVELOPMENTS 574
- 15.9 BAYER AG 575
- 15.9.1 COMPANY SNAPSHOT 575
- 15.9.2 PIPELINE PORTFOLIO 575
- 15.9.3 RECENT DEVELOPMENTS 575
- 15.10 CELLDEX THERAPEUTICS. 577
- 15.10.1 COMPANY SNAPSHOT 577
- 15.10.2 PIPELINE PORTFOLIO 577
- 15.10.3 RECENT DEVELOPMENTS 577
- 15.11 CELLECTIS 578
- 15.11.1 COMPANY SNAPSHOT 578
- 15.11.2 PIPELINE PORTFOLIO 578
- 15.11.3 RECENT DEVELOPMENTS 578
- 15.12 GILEAD SCIENCES, INC. 579
- 15.12.1 COMPANY SNAPSHOT 579
- 15.12.2 REVENUE ANALYSIS 579
- 15.12.3 PRODUCT PORTFOLIO 580
- 15.12.4 RECENT DEVELOPMENTS 580
- 15.13 GSK PLC. 581
- 15.13.1 COMPANY SNAPSHOT 581
- 15.13.2 REVENUE ANALYSIS 581
- 15.13.3 PRODUCT PORTFOLIO 582
- 15.13.4 RECENT DEVELOPMENTS 582
- 15.14 INCYTE. 583
- 15.14.1 COMPANY SNAPSHOT 583
- 15.14.2 REVENUE ANALYSIS 583
- 15.14.3 PRODUCT PORTFOLIO 584
- 15.14.4 RECENT DEVELOPMENTS 584
- 15.15 LILLY. 585
- 15.15.1 COMPANY SNAPSHOT 585
- 15.15.2 REVENUE ANALYSIS 586
- 15.15.3 PRODUCT PORTFOLIO 586
- 15.15.4 RECENT DEVELOPMENTS 587
- 15.16 NOVARTIS AG 588
- 15.16.1 COMPANY SNAPSHOT 588
- 15.16.2 REVENUE ANALYSIS 588
- 15.16.3 PIPELINE PORTFOLIO 589
- 15.16.4 PRODUCT PORTFOLIO 589
- 15.16.5 RECENT DEVELOPMENTS 589
- 15.17 PFIZER INC. 590
- 15.17.1 COMPANY SNAPSHOT 590
- 15.17.2 REVENUE ANALYSIS 590
- 15.17.3 PRODUCT PORTFOLIO 591
- 15.17.4 RECENT DEVELOPMENTS 591
16 QUESTIONNAIRE 592
17 RELATED REPORTS 596